Article

Campath 1-H treatment in patients with aggressive relapsing remitting multiple sclerosis.

Department of Neurology, University Hospital of Wales, Heath Park, Cardiff, UK.
Journal of Neurology (Impact Factor: 3.84). 02/2008; 255(2):231-8. DOI: 10.1007/s00415-008-0696-y
Source: PubMed

ABSTRACT Campath 1-H (Alemtuzumab) is a humanised monoclonal antibody which targets the CD52 antigen, a low molecular weight glycoprotein present on the surface of most lymphocyte lineages, causing complement mediated lysis and rapid and prolonged T lymphocyte depletion. Following encouraging initial data from other centres we report our open label experience of using Campath 1-H as a treatment in aggressive relapsing multiple sclerosis in a consecutive series of 39 highly selected patients treated across three regional centres and followed for a mean of 1.89 years. The mean annualised relapse rate fell from 2.48 pre treatment to 0.19 post treatment with 29% of documented relapses observed in the 12 weeks following initial infusion. Mean change in EDSS was -0.36 overall and -0.15 in those patients completing > or =1 year of follow- up. Eighty-three per cent of patients had stable or improved disability following treatment. Infusion related side effects were common including rash, headache and pyrexia but were usually mild and self limiting. Transient worsening of pre-existing neurological deficits during infusion was observed in 3 patients. 12 patients developed biochemical evidence of autoimmune dysfunction, 2 patients developed thyroid disease and 1 patient autoimmune skin disease. We conclude that relapse rates fall following Campath 1-H. Whilst side effects were common these were normally self limiting or easily managed, suggesting Campath 1-H may be of use in the treatment of very active relapsing remitting multiple sclerosis.

0 Bookmarks
 · 
93 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Multiple sclerosis (MS) is an inflammatory condition of the CNS presumably induced by an environmental trigger(s) in a genetically susceptible individual. Inflammation is prominent and most susceptible to intervention early in MS, so early treatment with disease-modifying therapies is recommended to reduce relapses and new MRI activity (both markers of inflammation) with the goal of delaying disability progression. Unfortunately, the response to the disease-modifying therapies is variable and often falls short of stopping observable disease activity, so the search for more effective agents continues. Alemtuzumab is a monoclonal antibody against CD52 that has exhibited significant efficacy throughout its clinical trial program in MS; uniquely, some of the studies have demonstrated a sustained reduction in disability in MS patients. Countering this impressive efficacy is an associated high risk of autoimmune events (especially thyroid) and concerns for infection or malignancy given prolonged immunosuppression after treatment with alemtuzumab.
    Expert Review of Clinical Immunology 08/2014; 10(10). DOI:10.1586/1744666X.2014.951332 · 3.34 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Monoclonal antibodies have rapidly developed as an important therapeutic strategy in multiple sclerosis (MS). As a result of an improved understanding of pathogenesis, a number of agents are now in the latter stages of development, which may allow a more targeted approach to forms of this disease resistant to other treatments. Alemtuzumab is the second to emerge for treatment of relapsing MS and has had a long and occasionally painful evolution toward wider availability. Even now it continues to court controversy, having been approved for use in Europe but, to the dismay of many specialists, let alone patients, having so far been denied a license in the United States, the US Food and Drug Administration (FDA) citing concerns about blinding in trial designs and frequency of adverse events.(1,2</SUP)
    Neurology 05/2014; 82(24). DOI:10.1212/WNL.0000000000000530 · 8.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Disease-modifying treatments for multiple sclerosis (MS) have now been available for almost 20 years. Interferon β (IFN-β) products and glatiramer acetate (GA) were the first available options and are now considered first-line agents for the treatment of MS. These medications have several years of favorable safety data, but are not effective in completely controlling disease activity in all patients. Alternate medications with increased efficacy have been developed and identified; however, these newer medications have known or potential safety concerns which have prompted clinicians to view them as second-line agents. Highly efficacious and safe medications are continuously being searched for and developed; however, time is needed to establish the long-term safety of any new therapeutic agent. MS practitioners are faced with the clinical dilemma of treating patients with very safe modestly effective medications or using more efficacious and potentially riskier agents. The risk-benefit profile of every medication will have to be weighed carefully and clinicians will need to gage the risk tolerance of each patient in order to tailor treatment. This review will summarize benefits and risks of recently approved therapies in MS and will provide a perspective view on the placement of these medications within the MS treatment algorithm in the near future.
    12/2012; 3(6):291-303. DOI:10.1177/2042098612462599

Full-text

Download
1 Download
Available from
Feb 21, 2015